On July 11th, Gelunhui announced that Zhejiang Hisun Pharmaceutical (600267.SH) has received the approval and issuance of the injection of Telavancin drug supplementary application approval notice from the National Medical Products Administration. The company's Telavancin injection has passed the generic drug quality consistency evaluation.
Telavancin injection is used for severe Gram-positive bacterial infections, including those who cannot use penicillin and cephalosporin antibiotics, or severe staphylococcal infections that cannot be treated with penicillin or cephalosporin antibiotics or have failed with the above antibiotics, or vancomycin-resistant staphylococcal infections. Telavancin has been proven effective in the following infections: skin and soft tissue infections, urinary tract infections, respiratory tract infections, sepsis, and peritoneal dialysis-related peritonitis. It can also be used for prophylaxis when Telavancin injectable is associated with high Gram-positive bacterial infection risk factors in orthopedic surgery.